Table 2.

Simulations scenarios following the idelalisib example: cumulative incidence of DLT at the end of the observation window (Obs. window) by dose level (D1 to D5), and by length of window. Maximum tolerated dose is given in bold.

		Cumulative incidence of DLT at the end of window
Obs. window	Hazard	D1	D2	D3	D4	D5
16 weeks	Constant (100% of toxicity events in [0,16w])	0.10	0.25	0.45	0.60	0.75
4 weeks	Decreasing (78% of toxicity events in [0,4w])	0.077	0.196	0.364	0.501	0.650
4 weeks	Decreasing (59% of toxicity events in [0,4w])	0.056	0.147	0.281	0.396	0.534
4 weeks	Constant (25% of toxicity events in [0,4w])	0.026	0.069	0.139	0.205	0.293